Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dimethaid Research has developed a new formulation of its topical osteoarthritis product Pennsaid in an effort to provide faster penetration to the treatment area.
Subscribe to our email newsletter
The new formulation, called Pennsaid Plus allows the main ingredient, diclofenac, to reach its target faster.
The company anticipates that it will take three to five years to obtain approval of the treatment by regulatory authorities in US, Canada and Europe. During this time Dimethaid will be conducting clinical trials to demonstrate the new product’s safety and efficacy.
Dr Henrich Guntermann, president and CEO of Dimethaid said: “With this new formulation, we anticipate that the faster penetration will result in a reduced dosage application. We also anticipate less skin irritation due to an improved humectant being added to the formula. We are taking an effective and safe product and making it even better.”
Dimethaid said original Pennsaid continues to capture an increased market share in Canada, and is also approved for sale in the UK, as well as a number of other European and Caribbean countries. The company is continuing its strategy to seek regulatory approval for Pennsaid in those key markets where approval has yet to be granted, including the US.